Fundraising Fox㈱PRISM BioLab
Tokyo, JP · 3 known investors
Find your way into ㈱PRISM BioLab
Sign up to see every warm intro you have to ㈱PRISM BioLab
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ㈱PRISM BioLab team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
Investors · 3
Newton Biocapitallisted by Newton BiocapitalBrussels
How we know: Newton Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does ㈱PRISM BioLab do?
- PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
- Who are ㈱PRISM BioLab's investors?
- ㈱PRISM BioLab's investors include DBJ Capital, Eisai Innovation, Inc., Newton Biocapital.
- Where is ㈱PRISM BioLab headquartered?
- ㈱PRISM BioLab is headquartered in Tokyo, JP.